title: Targeted therapeutics for severe refractory asthma: monoclonal antibodies.
abstract: Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary input for optimal clinical outcomes. Following multidimensional assessment for optimisation of current therapy, self-management skills and comorbidities, all patients should be accurately phenotyped. Only after this assessment has been completed should new monoclonal antibody therapies be considered. In this review, we summarise the new antibody approaches targeting identified pathological pathways in severe refractory asthma.
authors.affiliation: a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.|b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Grainge
authors.affiliation: a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
authors.forename: Steven
authors.initials: S
authors.lastname: Maltby
authors.affiliation: a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.|b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
authors.forename: Peter G
authors.initials: PG
authors.lastname: Gibson
authors.affiliation: a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.|b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
authors.forename: Peter A B
authors.initials: PA
authors.lastname: Wark
authors.affiliation: a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.|b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
authors.forename: Vanessa M
authors.initials: VM
authors.lastname: McDonald
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D058990:Molecular Targeted Therapy; D010641:Phenotype; D012648:Self Care / Q000379:methods; D012720:Severity of Illness Index
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal
keywords: Severe asthma; biomarker; monoclonal; multidimensional assessment; phenotype; targeted therapy; treatment-refractory asthma